CHEMOTHERAPY FOR BREAST CANCER

Pratibha Vannarwad; Akshata A. Lasure; Nandkishor B. Bavage; Shyamlila B. Bavage

CHEMOTHERAPY FOR BREAST CANCER

Authors: Pratibha Vannarwad, Akshata A. Lasure, Nandkishor B. Bavage, Shyamlila B. Bavage

Unique Paper ID: 152148
Volume: 8
Issue: 2
PageNo: 501-505

Keywords: Breast cancer cytotoxic chemotherapy metastatic breast carcinoma anthracycline chemotherapy.

Abstract:
Breast cancer represents a major health problem, with more than a million new cases and 370,000 deaths worldwide yearly. Breast cancer remains the most prevalent form of cancer among women. The use of cytotoxic chemotherapy in both advanced and early stage breast carcinoma has made significant progress in the last 10 years with several landmark studies identifying clear survival benefits for newer therapies. Cytotoxic combination regimens developed in the 1970s were shown to produce higher response rates and longer durations of response and survival than single agent therapy. These regimens became the standard of care for the management of metastatic hormone- refectory breast cancer and more recently for primary breast carcinoma, randomized trials also have demonstrated that anthracycline containing combination were more effective than combination without anthracyclins.The improvement in the understanding of the molecular biological basis of breast cancer provides possible targets for novel therapies.this review will focus on the evidence j use of chemotherapy.

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 8
Issue: 2
PageNo: 501-505

CHEMOTHERAPY FOR BREAST CANCER

Available:https://ijirt.org/Article?manuscript=152148

11 Jan, 2022

EVALUATION OF MARKETED EFFERVESCENT TABLETS

13 Oct, 2021

Bacterial Biofilm Inhibitor

02 Aug, 2021

The risk of death caused by the use of norepinephrine-resistant hypotension in the condition of septic shock in a patient

02 Aug, 2021

COMPUTER AIDED DRUG DESIGN (CADD)

29 Jul, 2021

Impact : Of Second Wave Covid-19 In world

29 Jul, 2021

The use of milrinone for curing a chronic heart failure

26 Jul, 2021

Leprosy Disease review

20 Jul, 2021

Transdermal Drug Delivery System

13 Jul, 2021

IBUPROFEN: AN OVERVIEW

13 Jul, 2021

USE OF HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY IN THE PHARMACEUTICAL INDUSTRY

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry